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 ABSTRACT 
 
 
 
In thyroid cancers there have been independent observations of the overexpression of a 
relatively uncharacterised proto-oncogene, known as PBF, as well as the deregulation of 
microRNAs. However, little remains known about how PBF is regulated although, a recent 
investigation has identified miR-122 to have the ability to regulate PBF in hepatitis B and 
liver cancer. 
 
Therefore, the aims of this investigation were to identify whether a selection of microRNAs 
can regulate PBF, altering its mRNA expression and protein levels. This was achieved by 
selecting microRNAs predicted to target PBF, transfecting SW1736 thyroid carcinoma and 
MCF7 breast carcinoma cell lines with microRNA mimics of these, then measuring PBF 
expression by qRT-PCR and Western blotting. 
 
The most striking result indicated that hsa-miR-122-5p caused a significant decrease in PBF 
 
protein levels cells despite no change in PBF mRNA expression. Furthermore, hsa-miR-124- 
 
3p and hsa-miR-506-3p also negatively regulated PBF mRNA expression and protein levels; 
highlighting microRNAs do have the ability to regulate PBF. Due to the emerging importance 
of microRNAs as biomarkers and therapeutics the identification of specific microRNAs that 
play a role in thyroid cancer may bear clinical relevance although, these initial findings need 
to be confirmed and extended for a more stringent investigation. 
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1. INTRODUCTION 
 
 
1.1. Thyroid Cancer 
 
 
Thyroid   cancers   are   a   rare   type   of   cancer   (http://www.cancerresearchuk.org/cancer- 
 
help/type/thyroid-cancer/about/thyroid-cancer-risks-and-causes) divided into four main 
 
groups  dependent  on  the  origin  of  the  cancer  cells  within  the  thyroid  gland,  which  is 
composed of parafollicular and follicular cells. Medullary thyroid carcinomas (MTC) are 
derived from parafollicular cells and are quite rare whereas tumours derived from follicular 
cells are more common and are divided into subtypes classified as; differentiated and 
undifferentiated carcinomas (Dvořáková, S., et al., 2014). Differentiated carcinomas include 
papillary thyroid carcinomas (PTC) and follicular thyroid carcinomas (FTC), which are slow 
growing and usually curable (Mazzaferri, E.L. and Kloos, R.T., 2001). The most common 
treatment for these is surgery followed by the use of radioiodine, which exploits the ability of 
the thyroid to take up iodine via the sodium iodide symporter (NIS) (Smith, V.E., et al., 
2013). In comparison, undifferentiated carcinomas - known as anaplastic thyroid carcinomas 
(ATC) - are extremely lethal as they are aggressive and metastasise, resulting in a median 
patient survival of less than six months (Lim, S.M., et al., 2012). 
 
There are multiple risk factors for thyroid cancer, including; a family history of thyroid 
cancer, an enlarged goitre and radiation exposure as well as being female, which results in 
thyroid  cancer  being  two  to  three  times  more  common  in  women  compared  to  men 
(http://www.cancerresearchuk.org/cancer-help/type/thyroid-cancer/about/thyroid-cancer- 
 
risks-and-causes). At the molecular level, it has been described that the genetics of thyroid 
 
cancer  also  act  as  risk  factors  with  genetic  alterations  described  to  be  apparent  in 
approximately 75% of cases (Bhaijee, F. and Nikiforov, Y.E., 2011, Read, M.L., et al., 2014). 
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Furthermore, the overexpression of certain proteins has also been observed in thyroid cancers, 
including  overexpression  of  the  proto-oncogene;  pituitary  tumor  transforming  gene  1 
(PTTG1) binding factor (PBF), also known as PTTG1 interacting protein (PTTG1IP). 
 
1.2. Pituitary Tumor Transforming Gene (PTTG) Binding Factor (PBF) 
 
 
PBF is a 180 residue long protein (Read, M.L., et al., 2011) with a molecular weight of 
approximately 25kDa (Smith V. and McCabe, C., 2008), which was first identified due to its 
interaction with PTTG1 via PBF’s C-terminus (Figure 1) (Chien, W. and Pei, L., 2000). This 
interaction between PTTG1 and PBF was described to induce the translocation of PTTG1 
from the cytoplasm into the nucleus (Stratford, A.L., et al., 2005) driving tumourigenesis 
(Smith, V.E., et al., 2011). As PBF has no significant homology to any other human protein 
(Read, M.L., et al., 2011), it has been described as a ‘relatively uncharacterised protein’ 
however, since it was recognised that PBF has a transforming ability of its own both in vitro 
and in vivo PBF has subsequently been defined as a proto-oncogene in its own right (Smith, 
V.E., et al., 2011), gaining increasing interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: PBF functional domains 
Schematic of signals and domains on PBF, responsible for its cellular location, as well as the 
PTTG1 binding site, found at the C-terminus. 
Smith V. and McCabe C., 2008. PTTG1IP (Pituitary Tumor-Transforming 1 Interacting Protein). 
Atlas of Genetics and Cytogenetics in Oncology and Haematology. (Image from: 
http://AtlasGeneticsOncology.org/Genes/PTTG1IPID41944ch21q22.html           accessed           on 
27/12/13). 
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1.2.1. PBF Expression in Thyroid Cancer 
 
 
The aforementioned overexpression of the proto-oncogene PBF within thyroid cancers, as 
well as breast cancers, is observed at both the mRNA expression and protein level, compared 
to the standard ubiquitous expression in normal thyroid tissue (Stratford, A.L., et al., 2005). 
This overexpression has been independently associated with a poor prognosis and lower 
disease-specific survival in thyroid cancers (Read, M.L., et al., 2014), likely due to the 
correlation with; distant metastases at diagnosis, tumour multicentricity and locoreginal 
recurrence (Hsueh, C., et al., 2013). Subsequently, this has resulted in PBF being described as 
a promising prognostic marker within thyroid cancer (Hsueh, C., et al., 2013), which is of 
interest due to the recent incidences of thyroid cancer increasing faster than that of any other 
malignancy in both genders and all ethnic backgrounds (Tuttle, R.M., 2013). 
 
Despite the precise role of PBF not being defined, investigations have begun to characterise 
PBF with respect to its roles in thyroid biology and tumourigenesis. One of the first functions 
of PBF defined with respect to thyroid cancer was its ability to act as a regulator of NIS. By 
preventing NIS function and expression at the plasma membrane PBF was consequently able 
to result in a repressed and insufficient radioiodine uptake during the treatment of 
differentiated thyroid cancers leading to a poor prognosis (Boelaert, K., et al., 2007). PBF has 
also been observed to interact with cortactin, a cytoplasmic protein involved in actin 
cytoskeleton rearrangement, thus facilitating cell migration and invasion (Sharma, N., et al., 
2012), making it unsurprising that PBF overexpression correlates with metastases (Hsueh, C., 
et al., 2013). Furthermore, in transgenic mice models where PBF is overexpressed in the 
thyroid gland an upregulation of Akt and the TSH receptor have been observed, which are 
known regulators of thyroid follicular cell  proliferation (Read, M.L., et al., 2011). 
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Most recently, PBF has been identified to be a regulator of the tumour suppressor p53 by 
specifically binding to p53 in thyroid cells and repressing transactivation of responsive 
promoters, as well as decreasing p53 stability via ubiquitination (Read, M.L., et al., 2014). 
This is an important finding as it has been well-documented that a disruption to p53 is 
observed in numerous cancers (Read, M.L., et al., 2014), highlighting the importance of 
regulating PBF due to the downstream impact it may have on tumourigenesis. 
 
Despite an overexpression of PBF being observed in thyroid and breast cancer, very little 
remains known about what causes PBF overexpression. Previously, it has been described that 
PBF has oestrogen response elements (ERE) within its promoter region, with a correlation 
observed between the number of EREs and PBF expression in ER-positive breast tumours, 
resulting in oestrogen-stimulated cell invasion (Watkins, R.J., et al., 2010). Furthermore, it 
has been observed that hsa-miR-122 can regulate PBF in chronic hepatitis B (CHB) and 
hepatocellular carcinomas (HCC) (Li, C., et al., 2012). 
 
1.3. MicroRNAs 
 
 
The observation of miR-122 regulating PBF is particularly interesting due to the increasing 
emergence of microRNAs being used as both biomarkers and therapeutics in cancer. 
Subsequently, recognition of the potential ability of microRNAs to regulate PBF contributed 
to the aims and hypotheses within this investigation, whereby the deregulation of specific 
microRNAs is hypothesised to result in PBF overexpression, as observed in thyroid cancer. 
 
MicroRNAs are short (21-25 nucleotides in length) non-coding RNAs that negatively regulate 
gene expression at the post-transcriptional level by binding to the 3’ UTR of their target 
mRNAs and preventing protein production (Cannell, I.G., et al., 2008) (Figure 2). As 
microRNAs account for 1-5% of the human genome (MacFarlane, L.A. and Murphy, P.R., 
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2010) and each microRNA has approximately 200 mRNA targets (Carther, R.W., 2006) they 
are able to target more than 60% of human protein-coding genes (Friedman, R.C., et al., 
2009). 
 
 
 
Figure  2:  MicroRNA  Targeting 
of mRNA 
Schematic of a microRNA (red) 
targeting the 3’ UTR of its mRNA 
target (grey), in this case PBF. 
This results in the prevention of 
translation and thus protein 
expression. 
 
 
 
 
 
 
 
 
 
 
 
Before targeting their mRNA target, microRNAs must be transcribed and processed from 
their own genes. In animals, microRNAs are transcribed by RNA polymerase II in the nucleus 
as a long polycistronic primary transcript with a hairpin (Lee, Y., et al., 2004) (Figure 3). 
Following transcription, the upper part of the hairpin is excised by Drosha, an RNase III 
enzyme in the nucleus, to give a 65 nucleotide intermediate known as pre-microRNA (Figure 
3). Exportin-5 then facilitates the export of pre-microRNAs from the nucleus into the 
cytoplasm (Yi, R. et al., 2003) where Dicer, another RNase III enzyme, removes the hairpin 
loop to give a RNA duplex (Cai, X., et al., 2004) (Figure 3). This duplex is then assembled 
into a protein complex known as the RNA-induced silencing complex (RISC), which contains 
Argonaute proteins (Ago (1-4)) at its centre used to separate the RNA duplex strands 
(Kawamata, T., et al., 2011). Subsequently, one strand of the duplex is degraded and the other 
strand remains as a mature microRNA guide strand (Figure 3), as determined by the internal 
stability of the duplex ends with a less stable 5’ end resulting in strand survival (Lee, Y., et 
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Figure 3: Pathway of microRNA processing 
Pathway of microRNA processing starting from the long primary transcript (pri-microRNA) in the 
nucleus,  which is  cleaved by Drosha to  give pre-microRNA. Exportin-5  along with Ran-GTP 
export pre-microRNA from the nucleus to the cytoplasm where Dicer cleaves the hairpin loop 
off to give the mature microRNA. The functional strand of the mature microRNA is then loaded 
onto Ago2 to form the RISC while the other strand gets degraded. RISC is then guided to its 
targets to cause mRNA target cleavage, translational repression or mRNA deadenylation. (Image 
from: Winter, J., et al., 2009. The Linear Canonical Pathway of MicroRNA Processing. Nature Cell 
Biology, 11, pp.228-234). 
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al., 2004). These processing steps ensure microRNA authenticity (Kawamata, T., et al., 2011) 
and guarantee the microRNA guide strand targets and binds the RISC to the correct mRNA 
target. This binding takes place via Watson-Crick base pairing, with a full-match base pairing 
between the seed region (residues 2-8 at the microRNA 5’ end) and 3’ UTR of the mRNA 
target, followed by a bulge region and then a region of partial complementarity (Ricci, E.P., et 
al., 2011). 
 
Upon successful targeting of the microRNA, protein production is prevented by one of three 
methods;   1)   slicer-dependent   mRNA   degradation,   2)   slicer-independent   translational 
repression or 3) mRNA degradation and translational repression in P-bodies (MacFarlane, 
L.A.  and  Murphy,  P.R.,  2010).  Slicer-dependent  mRNA  degradation  is  where  mRNA 
cleavage is catalysed by Ago2 in the RISC followed by the subsequent degradation of the 
mRNA products, which requires de-adenylation of the mRNA to remove the poly(A) tail 
making this an irreversible process (MacFarlane, L.A. and Murphy, P.R., 2010). In 
comparison, slicer-independent translational repression is due to the microRNA being bound 
to its mRNA target and physically preventing translation taking place. Although the exact 
mechanism remains unknown, it is known that Ago2 in the RISC has a cap-binding-like-motif 
making the 5’ cap of the target mRNA important for translational repression (Cannell, I.G., et 
al., 2008). However, once this repression is relieved the mRNA can be translated again 
making this a reversible process (MacFarlane, L.A. and Murphy, P.R., 2010). Finally, the 
third method microRNAs use to repress protein expression of their target mRNAs is; mRNA 
degradation and translational repression within P-bodies (Liu, J., et al., 2005). P-bodies are 
cytoplasmic domains that contain enzymes and factors within specialised compartments 
required for mRNA decapping, deadenylation, RNA degradation and translational repression 
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allowing  both  slicer-dependent  and  slicer-independent  silencing  to  take  place  inside 
 
(MacFarlane, L.A. and Murphy, P.R., 2010) 
 
 
1.3.1. MicroRNAs in Thyroid Cancer 
 
 
MicroRNAs have been observed to be downregulated in vivo in mouse models of thyroid 
cancer (Visone, R., et al., 2007); highlighting the significance of microRNAs in thyroid 
tumourigenesis. Furthermore, microRNA expression has been observed to differ between 
normal and cancerous thyroid tissue, with 32% of microRNAs being upregulated and 38% 
being downregulated in thyroid tumours compared to normal tissues (Nikiforova, M.N., et al., 
2009) and moreover, various microRNA signatures have been associated with each of the four 
groups of thyroid carcinomas; MTC, FTC, PTC and ATC (Abraham, D., et al., 2011, Jacques, 
C., et al., 2013, Visone, R., et al., 2007). Consequently, due to the observation of microRNA 
deregulation in thyroid cancers this has led to recognition of the use of microRNAs in both 
the diagnosis and prognosis of thyroid cancers (Leonardi, G.C., et al., 2012). 
 
1.4. Aims 
 
 
The aim of this investigation was to determine whether specifically selected microRNAs can 
regulate PBF, due to independent observations of microRNA deregulation and PBF 
overexpression in thyroid cancers, as well as the recent observation of a microRNA, miR-122, 
targeting PBF in liver cancer. To determine the ability of microRNAs to target PBF, 
microRNA mimics of specifically selected microRNAs, alongside an anti-PBF siRNA as a 
control, were transfected into SW1736 and MCF7 cells, then PBF mRNA expression and PBF 
protein levels were assessed by qRT-PCR and Western blotting respectively. 
 
It was hypothesised that PBF would be negatively regulated by the selected microRNAs and 
thus overexpression of these microRNAs by transfection would result in a decrease in PBF 
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mRNA expression and protein levels. Further investigations may determine whether there is a 
correlation between the downregulation of these microRNAs and PBF overexpression in 
thyroid cancer patient samples, which may consequently suggest clinical relevance due to the 
emergence of microRNAs as biomarkers and therapeutics in thyroid cancer. 
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2. MATERIALS & METHODS 
 
 
2.1. MicroRNA Selection 
 
 
Five microRNAs hypothesised to target PBF were selected by integrating results from the 
literature and prediction software, including; miRWalk (Dweep, H., et al., 2011), TargetScan 
(Friedman, R.C., et al., 2009), miRDB (Wang, X. and El Naga, I.M., 2008, Wang, X., 2008) 
and miRTarBase (Hsu, S.D., et al., 2010). In addition two controls were selected; a negative 
control  siRNA,  which  has  no  homology to  any  known  mammalian  genes  and  anti-PBF 
siRNA,  which  directly  targets  PBF.  These  both  identify  thresholds  for  the  effect  of 
microRNA mimics, predicted to target PBF, to be measured against. 
 
2.2. Cell Lines 
 
 
The  human  BRAFV600E  anaplastic  thyroid  carcinoma  cell  line  (SW1736)  and  human 
estrogen receptor positive breast adenocarcinoma cell line (MCF7), both derived from 
Caucasians, were obtained from the Cell Lines Services (#300453) and European Collection 
of  Cell  Cultures  (#86012803)  respectively.  They  were  maintained  in  RPMI  1640-L- 
Glutamine (Gibco) complete medium (10% FBS and 1% Penstrep) at 37
o
C and 5% CO2 and 
sub-cultured frequently to ensure 80% maximum confluency. 
 
 
2.2.1. Transfection 
 
 
24 hours before transfection, SW1736 and MCF7 cells were seeded at; 60,000 cells/well and 
 
62,500 cells/well in 1ml RPMI 1640-L-Glutamine complete medium in 12-well plates for 
RNA analysis respectively and 150,000 cells/well and 125,000 cells/well in 2ml RPMI 1640- 
L-Glutamine complete medium in 6-well plates for protein analysis respectively. Transfection 
mixes were made by diluting the microRNA mimic (hsa-miR-1, hsa-miR-122-5p, hsa-miR- 
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124-3p, hsa-miR-193b-5p or hsa-miR-506-3p (Qiagen)), AllStars negative control siRNA 
(Qiagen) or anti-PBF siRNA (Life Technologies) in opti-MEM for a final concentration of 
50nM. 12µl or 24µl HiPerfect transfection reagent (Qiagen)/well for 12-well or 6-well plates 
respectively was added to the transfection mixes, vortexed and incubated for 10 minutes 
according to the Qiagen protocol. Transfection mixes were then added in a dropwise manner 
to cells in a 12-well or 6-well plate. It is important to note that for RNA analysis, four 
replicates of each microRNA mimic and siRNA were transfected/experiment and for protein 
analysis one of each microRNA mimic and siRNA was transfected/experiment. Following 
transfection, cells were returned to 37
o
C and 5% CO2  for 48 or 72 hours prior to RNA 
 
isolation or protein harvesting respectively. 
 
 
2.3. RNA Analysis 
 
 
2.3.1. RNA Isolation 
 
 
48 hours after transfection, medium was aspirated from 12-well plates and cells were washed 
with PBS. PBS was aspirated and cells were lysed with 250µl TRI-Reagent (Sigma)/well at 
room temperature for 5 minutes. Lysates were transferred into Eppendorfs and stored at -80
o
C 
overnight. The next day the RNA isolation protocol was continued by adding 50µl chloroform 
(Sigma)/sample  and  incubating  at  room  temperature  for  5  minutes  for  phase  isolation. 
Samples were centrifuged at 13,000xg and the colourless aqueous phase was transferred to a 
clean Eppendorf. To precipitate the RNA 125µl isopropanol (Sigma)/sample was added and 
incubated at room temperature for 20 minutes, followed by centrifugation at 13,000xg for 15 
minutes. Supernatant was removed and the RNA pellet was washed with 250µl ethanol (VWR 
International)/sample for 5 minutes then left to air dry. Each sample was then re-suspended in 
 
20µl nuclease free water (ProMega) and RNA concentration was determined by NanoDrop. 
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2.3.2. Reverse Transcription PCR (RT-PCR) 
 
 
Reactions mixtures for RT-PCR for each RNA sample contained: 0.5µg RNA in 5µl nuclease 
free water, 2µl MgCl2, 1µl RT 10x buffer, 1µl dNTP mixture (10mM), 0.25µl Recombinant 
RNasin, 0.25µl AMV RT and 0.5µl random primers (Reverse Transcription System, 
Promega)). An AMV negative control reaction was made in the same way with a randomly 
selected duplicate 0.5µg RNA in 5µl nuclease free water, besides substituting AMV RT with 
nuclease free water. The Promega RT-PCR protocol was followed and reaction mixtures 
underwent the following RT-PCR programme: 42
o
C for 60 minutes, 95
o
C for 5 minutes, then 
4
o
C for 3 minutes, following which cDNA samples were made to a total volume of 50µl with 
 
nuclease free water. 
 
 
2.3.3. Quantitative Real-Time PCR (qRT-PCR) 
 
 
Within a PCR hood, reaction mixtures for qRT-PCR for each cDNA sample, including the 
AMV RT negative control, were added to a 96-well plate in duplicate for both PBF and 18S. 
Reaction mixtures contained: 2µl cDNA, 10µl 2x GoldStar TaqMan PCR mastermix 
(Eurogentec), 7µl nuclease free water and 1µl PTTG1IP TaqMan gene expression assay 
labelled with FAM dye (Life Technologies) or 1µl  Eukaryotic 18S rRNA endogenous control 
labelled with VIC dye (Life Technologies) for PBF or 18S respectively. Control reactions 
were also added to the 96-well plate in duplicate for PBF and 18S, made exactly the same, 
besides substituting 2µl cDNA with nuclease free water. Following this, plates were sealed, 
centrifuged  and  underwent  the  following  qRT-PCR  programme:  50
o
C  for  2  minutes  for 
 
optimal enzyme activity, 95
o
C for 10 minutes to activate the AmpliTaq Gold and then for the 
PCR; 40 cycles of 95
o
C for 15 seconds and 60
o
C for 1 minute to denature, anneal and extend 
DNA. 
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2.3.4. Statistics 
 
 
7500 system software was used to analyse qRT-PCR data (Supplementary figures 1 and 2), 
with PBF mRNA expression normalised against 18S (CT values between 9 and 10) for each 
sample. qRT-PCR duplicates were then averaged and ΔΔCT values and power calculations 
were completed on duplicate averages. Following this, duplicate averages for the four 
replicates of each microRNA mimic and siRNA transfected/experiment were averaged for a 
mean power value for each microRNA and siRNA, which was presented on a bar graph. The 
standard error mean (SEM) for each microRNA and siRNA was calculated using average 
duplicate ΔCT values and the significance of results was assessed using the two-tailed 
student’s t-test on these values, to a value of p<0.01, p<0.05 or non-significant. 
 
When averaging qRT-PCR data from all experiments, the mean power values for each 
microRNA and siRNA from individual experiments were averaged and presented on a bar 
graph with the SEM and two-tailed student’s t-test calculated using the average ΔCT values 
for each microRNA from each individual experiment. As before, significance was assessed to 
a value of p<0.01, p<0.05 or non-significant. 
 
2.4. Protein Analysis 
 
 
2.4.1. Protein Harvest 
 
 
72 hours after transfection, medium was aspirated from 6-well plates and cells were washed 
with PBS. PBS was aspirated and cells were lysed with 150µl RIPA buffer (1.22g Trizma 
base, 1.8g NaCl, 160ml dH2O – pH7.4, 2ml Igepal, 5ml sodium deoxycholate, 2ml 100mM 
EDTA and protease inhibitor cocktail (6:100 dilution (Sigma)))/well for 20 minutes at -20
o
C. 
 
Lysates were transferred into Eppendorfs, sonicated at 4
o
C for 1 minute on a medium setting 
using the Bioruptor Standard (Diagenode), centrifuged at 4
o
C at 13,000xg for 5 minutes and 
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lysates were collected. Protein concentrations were determined using the BCA protein assay 
 
(ThermoScientific). 
 
 
2.4.2. Western Blotting 
 
 
Antibody Company Dilution 
Rabbit anti-PBF In house 1:500 
(In 5% non-fat milk) 
Goat anti-rabbit Dako 1:2,000 
(In 5% non-fat milk) 
Mouse anti-β-actin Sigma 1:10,000 
(In 5% non-fat milk) 
Rabbit anti-mouse Dako 1:10,000 
(In 5% non-fat milk) 
 
Table 1: Antibodies 
All antibodies used within this investigation listed at the dilution used and 
the company antibodies were purchased from. 
 
30µg of each protein lysate in protein sample buffer (0.107g DTT (Sigma)/1ml Laemmli 
buffer (BioRad)) was incubated at 95
o
C for 5 minutes before being resolved on a 12% SDS- 
polyacrylamide gel. Proteins were transferred onto a PVDF membrane (GE Life Sciences) 
and probed with a rabbit anti-PBF primary antibody in 5% non-fat milk at room temperature 
for 1 hour, washed in TBST (50ml 1M Tris pH7.6, 20g 5mM NaCl, 0.625ml Tween-80 and 
2449.4ml dH2O) then probed with goat anti-rabbit antibody in 5% non-fat milk at room 
temperature for 1 hour. Membranes were incubated with Pierce® ECL2 Western blotting 
substrate (ThermoScientific), placed into a light-excluding cassette and exposed to x-ray film, 
which was developed by the Xograph Compact X4 film processor. 
 
Following washing in TBST, membranes were re-probed using murine anti β-actin antibody 
in 5% non-fat milk at room temperature for 1 hour, washed in TBST then probed with rabbit 
anti-murine antibody in 5% non-fat milk at room temperature for 45 minutes. Membranes 
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were incubated with Amersham ECL plus Western blotting substrate (GE Life Sciences) and 
developed as described above. 
 
2.4.3. Statistics 
 
 
Densitometry was completed on ImageJ to analyse Western blots, with PBF protein levels at 
 
25kDa and 30kDa (as these are the main forms of PBF studied (Watkins, R.J., et al., 2010) 
and identified by various antibodies by Western blot) normalised against β-actin. The fold- 
change relative to the negative control, assigned an arbitrary value of 1.0, was calculated for 
each microRNA or siRNA and presented on a bar graph. When averaging Western blots from 
all experiments, the fold-changes relative to the negative control for each microRNA or 
siRNA from individual experiments were averaged and presented on a bar graph, with the 
SEM and two-tailed student’s t-test completed using the fold-change values. Statistical 
significance was assessed to a value of p<0.01, p<0.05 or non-significant. 
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3. RESULTS 
 
 
 
3.1. MicroRNAs Predicted to Target PBF 
 
 
Five microRNAs predicted to target PBF were selected in this investigation, with the evidence 
and reasons for their selection based on prediction software and the literature, as shown 
below. 
 
3.1.1. hsa-miR-1 
 
 
MiRWalk identified hsa-miR-1 to be involved in a validated interaction with PBF (PTTG1IP) 
(Dweep, H., et al., 2011) (Figure 4A). Additionally, it has been described that miR-1 acts as a 
tumour suppressor in thyroid tumours due to a downregulation of miR-1 apparent in thyroid 
carcinomas compared to normal thyroid tissue (Leone, V., et al., 2011), highlighting this as a 
particularly interesting microRNA to investigate. 
 
 
 
A 
 
B 
 
 
 
 
Figure 4: Identification of PBF as a validated target of microRNA from miRWalk 
A) PTTG1IP/PBF is a validated target of hsa-miR-1 (Dweep, H., et al., 2011). 
B) PTTG1IP/PBF is a validated target of hsa-miR-124 (Dweep, H., et al., 2011). 
 
 
3.1.2. hsa-miR-122-5p 
 
 
hsa-miR-122-5p was not identified by the prediction software to target PBF however, as 
described previously, PBF has been shown to be regulated in CHB and HCC by miR-122. In 
addition, inhibition of miR-122 is described to cause an upregulation of PBF in HCC resulting 
in a promotion of tumour growth and invasion (Li, C. et al., 2012) making this a particularly 
interesting  microRNA  to  investigate  due  to  PBF  being  known  to  have    functions  in 
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proliferation and invasion. In addition, miR-122 has been observed to be downregulated in 
breast cancer and upon overexpression in vitro and in vivo inhibits breast cancer cell 
proliferation (Wang, B., et al., 2012), in line with the previous observations of PBF. 
 
3.1.3. hsa-miR-124-3p 
 
 
MiRWalk identified miR-124 to have a validated interaction with PBF (PTTG1IP) (Dweep, 
H., et al., 2011) (Figure 4B), with additional evidence from miRTarBase, in the form of a 
microarray,  highlighting  the  same  (Hsu,  S.D.,  et  al.,  2010).  Furthermore,  TargetScan 
identified the miR-124 binding site on PBF to be conserved as well as miR-124 itself defined 
as broadly conserved among vertebrates (Friedman, R.C., et al., 2009) (Figure 5A), which is 
suggestive of an important role in regulating the genome and more specifically, PBF. In the 
literature, miR-124 has been described to have a role as a tumour suppressor in various 
cancers by modulating the proliferation and aggressiveness of tumours (Xu X., et al., 2013). 
 
 
 
 
 
 
A 
 
 
 
B 
 
 
 
Figure 5: Broadly conserved microRNA among vertebrates predicted by TargetScan to target PBF 
A) miR-124 and miR-506 are ranked to be broadly conserved microRNAs in vertebrates predicted to 
target PBF (Friedman, R.C., et al., 2009). 
B) miR-193b is also ranked to be a broadly conserved microRNA in vertebrates predicted to target 
PBF (Friedman, R.C., et al., 2009). 
 
 
 
3.1.4. hsa-miR-193b-5p 
 
 
The miR-193 family, including miR-193b, was predicted by TargetScan to bind to PBF at a 
poorly conserved site (Friedman, R.C., et al., 2009) (Figure 5B). However, despite having a 
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poorly conserved binding site on PBF, the miR-193 family is conserved among mammals 
(Friedman, R.C., et al., 2009) suggestive of an important functional role. The literature 
described miR-193b to target oestrogen receptor α (ER-α), resulting in an inhibition of 
oestrogen-induced growth of breast tissue tumours (Leivonen, S-K., et al., 2011) (Yoshimoto, 
N., et al., 2011), which may be pertinent given that PBF is upregulated in ER-α positive 
MCF7 cells (Watkins, R.J., et al., 2010). 
 
3.1.5. hsa-miR-506-3p 
 
 
hsa-miR-506 has sequence similarity with hsa-miR-124, resulting in both these microRNAs 
predicted to bind to the same conserved site on the 3’ UTR of PBF as well as both being 
broadly conserved among vertebrates (Friedman, R.C., et al., 2009) (Figure 5A). Furthermore, 
hsa-miR-506 has been implicated in suppressing epithelial-mesenchymal transition (EMT) in 
breast cancer cell lines (Arora, H., et al., 2013) highlighting an importance in cell invasion 
and migration, which correlates with the observations of PBF playing a role in invasion 
(Watkins, R.J., et al., 2010). 
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3.2. Effect on PBF mRNA Expression Following MicroRNA Mimic Transfections 
 
 
3.2.1. Effect on PBF mRNA Expression Following MicroRNA Mimic Transfections in SW1736 
 
Cells 
 
 
Following the first experiment in SW1736 cells a 94.50% decrease (p>0.01) in PBF mRNA 
expression was observed as a result of anti-PBF siRNA transfection (Figure 6). Despite this, 
no significant changes in PBF mRNA expression were observed following any of the 
microRNA mimic transfections (Figure 6). However, due to technical issues with the RNA 
isolation and thus RNA quality in this experiment, these results were not thought to be 
reliable and were not been included in any further analysis. 
 
 
 
 
 
 Neg CTL MiR-1 MiR-122 MiR-124 MiR-193b MiR-506 Anti-PBF 
ΔCT 11.58 12.95 10.80 13.09 10.45 11.84 15.88 
SEM 0.42 0.46 0.30 0.45 0.27 0.14 0.32 
 
Figure 6: PBF mRNA Expression in SW1736 cells following transfection with five microRNAs 
PBF mRNA expression in SW1736 cells following the first experiment with (L-R): Negative control 
(Neg CTL), hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-193b- 
5p (MiR-193b), hsa-miR-506-3p (MiR-506) and anti-PBF siRNA (Anti-PBF) normalised to 18S. ΔCT 
indicates PBF CT value – 18S CT value and SEM indicates the SEM of the four replicates for each 
sample. Statistics were calculated using the paired t-test, where ***=p<0.01 and ns=non-significant. 
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 Neg CTL MiR-1 MiR-122 MiR-124 MiR-193b MiR-506 Anti-PBF 
ΔCT 10.22 10.64 10.51 11.22 10.05 11.26 11.87 
SEM 0.31 0.28 0.46 0.38 0.08 0.15 0.10 
 
 
 
The second experiment in SW1736 cells indicated a significant decrease in PBF mRNA 
expression following transfection with anti-PBF siRNA of 70.77% (p<0.01) as well as a 
significant decrease following the transfection with hsa-miR-506-3p of 55.00% (p<0.05). In 
addition, albeit non-significant, a decrease in PBF mRNA expression was observed following 
hsa-miR-1 and hsa-miR-124-3p transfection of 3.72% and 33.20% respectively (Figure 7). 
 
 
 
 
 
 
 
 
 
 
Figure 7: PBF mRNA Expression in SW1736 cells following transfection with five microRNAs 
PBF mRNA expression in SW1736 cells following the second experiment with (L-R): Negative control 
(Neg CTL), hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-193b- 
5p (MiR-193b), hsa-miR-506-3p (MiR-506) and anti-PBF siRNA (Anti-PBF) normalised to 18S. ΔCT 
indicates PBF CT value – 18S CT value and SEM indicates the SEM of the four replicates for each 
sample. Statistics were calculated using the paired t-test, where ***=p<0.01, *=p>0.05 and ns=non- 
significant. 
 
 
 
 
In the third experiment in SW1736 cells, hsa-miR-193b-5p was not investigated as the 
transfection reagent was limited meaning the microRNA mimic with the least success thus far 
was sacrificed. The other microRNA mimics were transfected as before, with very small 
changes in PBF mRNA expression following transfection observed (Figure 8). However, 
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 Neg CTL MiR-1 MiR-122 MiR-124 MiR-506 Anti-PBF 
ΔCT 11.15 10.97 11.29 10.91 11.31 13.08 
SEM 0.09 0.09 0.22 0.19 0.09 0.18 
 
 
following anti-PBF siRNA transfection a decrease in mRNA expression of 72.72% (p<0.05) 
 
was observed (Figure 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8: PBF mRNA Expression in SW1736 cells following transfection with four microRNAs 
PBF mRNA expression in SW1736 cells following the third experiment with (L-R): Negative 
control (Neg CTL), hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), 
hsa-miR-506-3p (MiR-506) and anti-PBF siRNA (Anti-PBF) normalised to 18S. ΔCT indicates PBF 
CT value – 18S CT value and SEM indicates the SEM of the four replicates for each sample. 
Statistics were calculated using the paired t-test, where *=p<0.05 and ns=non-significant. 
 
 
 
 
Following the fourth experiment in SW1736 cells, where hsa-miR-193b-5p was also not 
investigated, anti-PBF siRNA caused a decrease in PBF mRNA expression of 61.00% 
(p<0.05). In addition, hsa-miR-122-5p, hsa-miR-124-3p and hsa-miR-506-3p caused 
significant decreases in PBF mRNA expression of 35.80% (p<0.05), 46.97% (p<0.05) and 
42.45% (p<0.05) respectively (Figure 9). In addition, hsa-miR-1 also caused a decrease in 
PBF mRNA expression of 39.43% (non-significant) (Figure 9), however this was non- 
significant. 
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 Neg CTL MiR-1 MiR-122 MiR-124 MiR-506 Anti-PBF 
ΔCT 10.10 10.93 10.73 11.08 10.95 11.80 
SEM 0.17 0.37 0.17 0.32 0.11 0.58 
 
 
 
 
 
 
 
 
Figure 9: PBF mRNA Expression in SW1736 cells following transfection with four microRNAs 
PBF mRNA expression in SW1736 cells following the fourth experiment with (L-R): Negative control 
(Neg CTL), hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-506-3p 
(MiR-506) and anti-PBF siRNA (Anti-PBF) normalised to 18S. ΔCT indicates PBF CT value – 18S CT value 
and SEM indicates the SEM of the four replicates for each sample. Statistics were calculated using the 
paired t-test, where *=p<0.05 and ns=non-significant. 
 
 
Average PBF mRNA expression levels were calculated using results from the second, third 
and fourth experiments, due to technical issues with the RNA from the first experiment. These 
results can be seen in Figure 10A, with the overall averages and statistics of these in Figure 
10B, indicating none of the microRNA mimics caused a significant change in PBF mRNA 
expression levels overall. The largest decrease in PBF mRNA expression of 35.54% (non- 
significant) was observed as a result of hsa-miR-506-3p transfection (Figure 10B). However, 
it is important to note that anti-PBF siRNA caused a significant decrease in PBF mRNA 
expression levels of 68.16% (p<0.05) (Figure 10B), around the value expected from a siRNA. 
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 Neg CTL MiR-1 MiR-122 MiR-124 MiR-193b MiR-506 Anti-PBF 
ΔCT 10.48802 10.84613 10.84204 11.06813 10.054 11.17333 12.24775 
SEM 0.330589 0.105105 0.23377 0.089388  0.112329 0.414503 
 
 
Figure 10: Average relative PBF mRNA expression following all three transfections in SW1736 
cells, with results averaged and analysed 
A) Results on relative PBF protein levels following transfection with a negative control (Neg CTL), 
hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-193b-5p, hsa- 
miR-506-3p (MiR-506) and anti-PBF siRNA (Anti-PBF) (n=3 for all microRNA, except miR-193b-5p 
(n=1)). 
B) Average PBF mRNA expression (n=3 for all microRNA, except miR-193b-5p (n=1)), calculated 
using results in A, with statistics calculated using the paired t-test, where *=p<0.05 and ns=non- 
significant. ΔCT indicates average ΔCT values from three experiments and SEM indicates the SEM 
from the three experiments. Statistics were calculated using the paired t-test, where *=p<0.05 and 
ns=non-significant. 
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3.2.2. Effect on PBF mRNA Expression Following MicroRNA Mimic Transfections in MCF7 
 
Cells 
 
 
Figure 11 indicates a decrease in PBF mRNA expression of 60.30% (non-significant) 
following anti-PBF siRNA transfection, as expected. However, none of the transfections with 
microRNA mimics caused a significant decrease in PBF mRNA expression, with the largest 
decreases in PBF mRNA expression observed following hsa-miR-124-3p and hsa-miR-506- 
3p transfections causing decreases in PBF mRNA expression of 18.97% (non-significant) and 
 
59.20% (non-significant) respectively (Figure 11). 
 
 
 
 Neg CTL MiR-1 MiR-122 MiR-124 MiR-506 Anti-PBF 
ΔCT 11.89 12.19 12.43 12.80 12.70 13.04 
SEM 0.35 0.29 0.21 0.16 0.30 0.63 
 
 
Figure 11: PBF mRNA Expression in MCF7 cells following transfection with four microRNAs 
PBF mRNA expression in MCF7 cells following the first experiment with (L-R): Negative control (Neg 
CTL), hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-506-3p 
(MiR-506) and anti-PBF siRNA (Anti-PBF) normalised to 18S. ΔCT indicates PBF CT value – 18S CT 
value and SEM indicates the SEM of the four replicates for each sample. Statistics were calculated 
using the paired t-test, where ns=non-significant. 
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 Neg CTL MiR-1 MiR-122 MiR-124 MiR-506 Anti-PBF 
ΔCT 12.45 12.19 12.43 13.19 12.22 12.87 
SEM 0.12 0.29 0.21 0.18 0.57 0.45 
 
 
Following the second experiment in MCF7, despite a non-significant 16.62% decrease in PBF 
mRNA expression following anti-PBF siRNA transfection, a significant decrease in PBF 
mRNA expression of 37.75% (p<0.05) was observed following transfection with hsa-miR- 
124-3p (Figure 12).  In comparison, following transfection with the other microRNA mimics; 
hsa-miR-1, hsa-miR-122-5p and hsa-miR-506-3p all caused an increase in PBF mRNA 
expression (Figure 12). 
 
 
 
 
 
 
 
Figure 12: PBF mRNA Expression in MCF7 cells following transfection with four microRNAs 
PBF mRNA expression in MCF7 cells following the second experiment with (L-R): Negative control 
(Neg CTL), hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-506- 
3p (MiR-506) and anti-PBF siRNA (Anti-PBF) normalised to 18S. ΔCT indicates PBF CT value – 18S CT 
value and SEM indicates the SEM of the four replicates for each sample. Statistics were calculated 
using the paired t-test, where *=p>0.05 and ns=non-significant. 
 
 
Overall average results for the effect of microRNA mimic transfections on PBF mRNA 
expression in MCF7 cells were not completed as there were only two sets of data and thus a 
meaningful  average  could  not  be  obtained.  However,  hsa-miR-124-3p  was  only  the 
microRNA that decreased PBF mRNA expression in both experiments in MCF7 cells. 
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3.3. Effect on PBF Protein Levels Following MicroRNA Mimic Transfections 
 
 
It is important to note there are multiple forms of PBF protein, which are recognised by the 
PBF antibody used during Western blotting - due to PBF having phosphorylation sites, five 
glycosylation sites as well as the ability to oligomerise (Smith V. and McCabe, C., 2008). 
However, the two species that were studied in this investigation were at 25kDa and 30kDa, as 
these are the main forms normally studied (Watkins, R.J., et al., 2010) and identified by 
Western blot by other commercially available antibodies. 
 
3.3.1. Effect on PBF Protein Levels Following MicroRNA Mimic Transfections in SW1736 
 
Cells 
 
 
Figure 13A shows the Western blot following the first experiment in SW1736 cells, 
highlighting the 25kDa and 30kDa PBF protein bands alongside β-actin. The largest overall 
effect on PBF protein levels was observed following hsa-miR-122-5p and hsa-miR-124-3p 
transfection (Figure 13A). Densitometry indicated that at 25kDa and 30kDa, hsa-miR-122-5p 
caused decreases in PBF protein of 58.30% at 25kDa and 79.66% at 30kDa and hsa-miR-124- 
3p caused a decrease of 65.70% and 78.11% at 30kDa (Figure 13B). Furthermore, hsa-miR- 
 
506-3p also caused large decreases in PBF protein levels at 25kDa and 30kDa of 89.97% and 
 
45.93% respectively (Figure 13B). In addition, following the anti-PBF siRNA transfection a 
decrease in PBF protein levels of 65.77% at 25kDa and 66.47% at 30kDa (Figure 13B) was 
observed, as would be expected. 
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Figure 13: PBF protein levels 
in SW1736 cells following 
transfection with five 
microRNAs 
A) Western blot showing PBF 
protein      levels      (*=25kDa, 
*=30kDa)   in   SW1736   cells 
following the first experiment 
with (L-R): Negative control 
(Neg CTL), hsa-miR-1 (MiR-1), 
hsa-miR-122-5p (MiR-122), 
hsa-miR-124-3p (MiR-124), 
hsa-miR-193b-5p (MiR-193b), 
hsa-miR-506-3p       (MiR-506) 
and   anti-PBF   siRNA   (Anti- 
PBF).  Anti-β-actin  at  44kDa       B 
shows   approximately   equal 
loading. 
B) Densitometry of Western 
blot normalised to β-actin 
showing PBF protein levels at 
25kDa and 30kDa in SW1736 
cells relative to the negative 
control, assigned an arbitrary 
value of 1. 
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Figure 14A shows the 25kDa and 30kDa PBF protein bands on the Western blot alongside β- 
actin following the second experiment in SW1736 cells. Figure 14B displays the densitometry 
from this Western blot indicating a decrease in PBF protein levels following transfection with 
hsa-miR-1 of 28.42% at 25kDa and 67.27% at 30kDa and hsa-miR-122-5p of 16.34% at 
25kDa and 2.31% at 30kDa (Figure 14B). However, hsa-miR-124-3p, hsa-miR-193b-5p and 
hsa-miR-506-3p all caused an increase in PBF protein levels at 25kDa and 30kDa. 
Furthermore, unexpectedly, anti-PBF siRNA resulted in an increase in PBF protein levels of 
126.01% at 25kDa and 136.08% at 30kDa (Figure 14B) creating some doubt as to how 
reliable these results are as a decrease following anti-PBF siRNA transfection would be 
expected as observed for mRNA expression levels following anti-PBF transfection, which 
was completed at the same time (Figure 10). 
 
 
 
Figure  14:  PBF  protein  levels  in                 A 
SW1736           cells           following 
transfection with five microRNAs 
A)   Western   blot   showing   PBF 
protein levels (*=25kDa, *=30kDa) 
in   SW1736   cells   following   the 
second   experiment with (L-R): 
Negative  control  (Neg  CTL),  hsa- 
miR-1 (MiR-1), hsa-miR-122-5p 
(MiR-122),   hsa-miR-124-3p   (MiR- 
124), hsa-miR-193b-5p (MiR-193b), 
hsa-miR-506-3p  (MiR-506)  and 
anti-PBF siRNA (Anti-PBF). Anti-β- 
actin at  44kDa shows 
approximately equal loading. 
B) Densitometry of Western blot 
normalised to β-actin showing PBF 
protein levels at 25kDa and 30kDa 
in SW1736 cells relative to the 
negative control, assigned an 
arbitrary value of 1. 
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Figure 15A shows the Western blot following the first experiment in SW1736 cells, 
highlighting the 25kDa and 30kDa PBF protein bands alongside β-actin. It is important to 
note that hsa-miR-193b-5p was not investigated in this experiment, as transfection reagent 
was limited - as described previously. Densitometry indicates decreased PBF protein levels 
following transfection with hsa-miR-122-5p of 37.27% at 25kDa and 5.65% at 30kDa and 
with hsa-miR-124-3p of 34.35% at 25kDa and 39.92% at 30kDa respectively (Figure 15B). In 
addition, following anti-PBF siRNA transfection a 49.85% decrease at 25kDa and a 0.24% 
decrease at 30kDa in PBF protein levels was observed (Figure 15B). 
 
 
 
Figure 15: PBF protein levels in 
SW1736 cells following transfection 
with four microRNAs 
A) Western blot showing PBF protein 
levels  (*=25kDa,  *=30kDa)  in 
SW1736 cells following the third 
experiment with (L-R): Negative 
control (Neg CTL), hsa-miR-1 (MiR-1), 
hsa-miR-122-5p (MiR-122), hsa-miR- 
124-3p (MiR-124), hsa-miR-506-3p 
(MiR-506) and anti-PBF siRNA (Anti- 
PBF). Anti-β-actin at 44kDa shows 
approximately equal loading. 
B) Densitometry of Western blot 
normalised to β-actin showing PBF 
protein levels at 25kDa and 30kDa in 
SW1736 cells relative to the negative 
control, assigned an arbitrary value 
of 1. 
B 
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A 
 
Following the fourth experiment in SW1736 cells, the 25kDa PBF protein band, which was 
previously identified and quantified, was not visible by Western blot. Therefore, only the 
30kDa PBF protein band (Figure 16A) was quantified by densitometry (Figure 16B). Results 
indicated  the  anti-PBF  siRNA  transfection  caused  an  increase  in  PBF  protein  levels  of 
104.51%  (Figure  16B),  similar  to  the  previous  unexpected  observation  (Figure  14B). 
However, despite this, a decrease in PBF protein levels at 30kDa was observed following 
transfection  with  hsa-miR-124  and  hsa-miR-506-3p  of  9.55%  and  29.46%  respectively 
(Figure 16B). 
 
 
 
Figure  16:  PBF  protein  levels  in 
SW1736  cells  following 
transfection with four microRNAs 
A)   Western   blot   showing   PBF 
protein levels (*=30kDa) in 
SW1736 cells following the fourth 
experiment  with   (L-R):   Negative 
control (Neg CTL), hsa-miR-1 (MiR- 
1), hsa-miR-122-5p (MiR-122), hsa- 
miR-124-3p   (MiR-124),   hsa-miR- 
506-3p   (MiR-506)   and   anti-PBF 
siRNA  (Anti-PBF).  Anti-β-actin  at 
44kDa shows approximately equal 
loading. 
B)  Densitometry  of  Western  blot 
normalised to β-actin showing PBF 
protein levels at 30kDa in SW1736 B 
cells relative to the negative 
control, assigned an arbitrary 
value of 1. 
 
 
 
 
 
 
 
 
 
 
The results from the four experiments above on PBF protein levels at 25kDa in SW1736 cells 
are  shown  together  in  Figure  17A;  indicating  experiment  two  as  a  potential  anomaly. 
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However, due to small n numbers making it difficult to determine a true anomaly, results were 
averaged from all sets of data and statistics completed (Figure 17B), indicating a significant 
average  decrease  in  PBF  protein  levels  following  transfection  with  hsa-miR-122-5p  of 
37.32±12.10 (p>0.05) (Figure 17B). In addition, hsa-miR-124-3p and hsa-miR-506-3p caused 
an average decrease of 26.21±25.48% (non-significant) and 33.66±38.85% (non-significant) 
(Figure 17B), albeit non-significant. The average decrease in PBF protein levels at 25kDa 
following transfection  with anti-PBF siRNA was 29.87±28.32% (non-significant) (Figure 
17B), lower than expected. 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Average relative PBF protein levels (25kDa) following all three experiments in SW1736 
cells, with results averaged and analysed 
A) Results on relative PBF protein levels following transfection with a negative control (Neg CTL), 
hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-193b-5p, hsa- 
miR-506-3p (MiR-506) and anti-PBF siRNA (Anti-PBF) (n=3 for all microRNA, besides miR-193b-5p 
(n=2)). 
B) Average PBF protein levels (n=3 for all microRNA, besides miR-193b-5p (n=2)), calculated using 
results in A, with statistics calculated using the paired t-test, where *=p<0.05 and ns=non-significant 
and error bars are calculated from the SEM. 
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The results from the four experiments above on PBF protein levels at 30kDa in SW1736 cells 
are shown in Figure 18A, highlighting experiment two as a potential anomaly, similarly to 
what was shown in Figure 17A. However, results were averaged from all sets of data and 
statistics completed (Figure 18B), which indicated none of the microRNA mimics or anti-PBF 
siRNA caused a significant average decrease in PBF protein levels at 30kDa. The largest 
average decrease in PBF protein levels was due to hsa-miR-124-3p, which caused a decrease 
of 16.35±29.70% (non-significant) at 30kDa (Figure 18B). 
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Figure 18: Average relative PBF protein levels (30kDa) following all four experiments in SW1736 
cells, with results averaged and analysed 
A) Results on relative PBF protein levels following transfection with a negative control (Neg CTL), 
hsa-miR-1 (MiR-1), hsa-miR-122-5p (MiR-122), hsa-miR-124-3p (MiR-124), hsa-miR-193b-5p, hsa- 
miR-506-3p (MiR-506) and anti-PBF siRNA (Anti-PBF) (n=4 for all microRNA, besides miR-193b-5p 
(n=2)). 
B) Average PBF protein levels (n=3 for all microRNA, besides miR-193b-5p (n=2)), calculated using 
results in A, with statistics calculated using the paired t-test, where ns=non-significant and error 
bars are calculated from the SEM. 
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When observing the effect of microRNA mimics on PBF protein levels at both 25kDa and 
 
30kDa, it appeared that all the selected microRNA mimics had a greater effect at 25kDa 
(Figure 19). Overall, hsa-miR-122-5p, hsa-miR-124-3p and hsa-miR-506-3p transfections all 
caused a similar degree of effect on PBF protein levels at 25kDa and 30kDa, which was 
comparable to the effect following anti-PBF siRNA transfection (Figure 19) suggestive of a 
potential of these microRNAs in regulating PBF. 
 
 
 
 
Figure 19: Comparison of average relative PBF protein levels (25kDa and 30kDa) following 
experiments in SW1736 cells 
Average PBF protein levels (From Figure 17B and Figure 18B, with statistics calculated using the 
paired t-test, where *=p<0.05 and ns=non-significant and error bars are calculated from the 
SEM. 
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3.3.2. Effect on PBF Protein Levels Following MicroRNA Mimic Transfections in MCF7 
 
Cells 
 
 
The Western blot following the first experiment in MCF7 cells can be seen in Figure 20A, 
with the 25kDa and 30kDa PBF protein bands highlighted alongside β-actin. Densitometry 
indicated all transfections caused large increases in PBF protein levels at both 25kDa and 
30kDa  (Figure  20B),  highlighting  there  may  have  been  a  technical  issue  with  these 
 
transfections as even the anti-PBF siRNA caused an increase in the surplus of 700%. 
 
 
 
 
Figure 20: PBF protein levels in 
MCF7  cells  following 
transfection with four 
microRNAs 
A)  Western  blot  showing  PBF 
protein        levels        (*=25kDa, 
*=30kDa) in MCF7 cells following 
the first experiment with (L-R): 
Negative control (Neg CTL), hsa- 
miR-1 (MiR-1), hsa-miR-122-5p 
(MiR-122),  hsa-miR-124-3p 
(MiR-124),  hsa-miR-506-3p 
(MiR-506) and anti-PBF siRNA 
(Anti-PBF). Anti-β-actin at 44kDa 
shows approximately equal 
loading. 
B) Densitometry of Western blot     B 
normalised  to  β-actin  showing 
PBF protein levels at 25kDa and 
30kDa in MCF7 cells relative to 
the negative control, assigned an 
arbitrary value of 1. 
 
 
 
 
 
 
 
Following the second experiment in MCF7 cells, the Western blot indicated the 30kDa PBF 
protein band (Figure 21A) but the PBF antibody did not identify the 25kDa PBF protein band, 
as seen previously in Figure 16A. Despite this, densitometry was completed for the 30kDa 
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PBF protein band, which indicated only hsa-miR-1 caused a small decrease in PBF protein 
 
levels of 12.95% (Figure 21B). 
 
 
 
Figure 21: PBF protein levels in                                        A 
MCF7           cells           following 
transfection with four 
microRNAs 
A) Western blot showing PBF 
protein  levels  (*=30kDa)  in 
MCF7 cells following the second 
experiment with (L-R): Negative 
control (Neg CTL), hsa-miR-1 
(MiR-1),  hsa-miR-122-5p  (MiR- 
122),     hsa-miR-124-3p     (MiR- 
124), hsa-miR-506-3p (MiR-506) 
and anti-PBF siRNA (Anti-PBF). 
Anti-β-actin at 44kDa shows 
approximately equal loading. 
B)   Densitometry   of   Western 
blot normalised to β-actin 
showing  PBF  protein  levels  at 
30kDa in MCF7 cells relative to 
the  negative  control,  assigned 
an arbitrary value of 1. 
 
 
 
 
 
 
 
 
Average results of the effect of microRNA mimic transfections on PBF protein levels in 
MCF7 cells was not completed due to two reasons: firstly, only one data set was available for 
the 25kDa PBF protein band and secondly, the 30kDa protein band gave variable results 
within the two sets of results making it impossible to obtain a true average result. 
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4. DISCUSSION 
 
 
 
Due to the observation of PBF being overexpressed in thyroid cancers (Smith, V.E., et al., 
 
2013) and microRNAs being described to be deregulated in thyroid cancers (Vriens, M.R., et 
al.,  2012),  it  was  hypothesised  that  there  may  be  a  correlation  between  microRNA 
deregulation and PBF overexpression. Therefore, this investigation was designed to identify 
microRNAs that target PBF as well as challenging the findings of Li, C., et al., who described 
PBF as a target of hsa-miR-122 in liver cancer (2013). Consequently, in this investigation, it 
was identified that hsa-miR-122-5p, hsa-miR-124-3p and hsa-miR-506-3p all targeted PBF to 
some degree, resulting in decreased PBF mRNA expression and/or protein levels. 
Subsequently, this may highlight a mechanism for the regulation of PBF, which is currently 
fairly elusive, whereby microRNA deregulation contributes to the overexpression of PBF, 
leading to thyroid cancer. 
 
4.1. hsa-miR-122-5p Decreased PBF Protein Levels 
 
 
The most striking average decrease in PBF protein levels following microRNA mimic 
transfection  was  observed  following  transfection  with  hsa-miR-122-5p  in  SW1736  cells, 
which caused a significant decrease in PBF protein levels at 25kDa of 37.32±12.10 (p>0.05), 
which  was  greater  than  the  average  decrease  following  anti-PBF  siRNA  transfection  of 
29.87±28.32% (non-significant) (Figure 17B). 
 
 
However, a similar effect of hsa-miR-122-5p against PBF was not observed at 30kDa (Figure 
 
18) in SW1736 cells or at 25kDa or 30kDa in MCF7 cells (Figures 20 and 21). Subsequently, 
further investigations would need to take place in both these cell lines, particularly MCF7 
cells to increase the number of repeats before a full conclusion could be made on whether hsa- 
miR-122-5p targets PBF. In addition, it would be essential to extend the investigation to study 
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the other forms of PBF protein, including the larger protein bands representing dimers, as in 
this  investigation  limitations  meant  only  the  main  forms  of  PBF  at  25kDa  and  30kDa 
(Watkins, R.J., et al., 2010) were observed. 
 
Furthermore, despite the decrease in PBF protein levels at 25kDa, it is important to note that 
PBF mRNA expression levels were not significantly altered by hsa-miR-122-5p in this 
investigation, with an average decrease of only 9.07% (non-significant) observed following 
transfection in SW1736 cells (Figure 10). This may indicate that PBF is not being directly 
targeted  by  hsa-miR-122-5p,  but  instead  is  being  affected  by  hsa-miR-122-5p  targeting 
another protein or pathway, which subsequently alters PBF protein levels. This is possible as 
each microRNA has approximately 200 mRNA targets (Carther, R.W., 2006), meaning even 
if PBF was directly targeted by hsa-miR-122-5p other mRNAs would also be targeted. To 
confirm  whether  PBF  is  being  targeted  directly  by hsa-miR-122-5p,  a  green  fluorescent 
protein (GFP) reporter assay could be used, by sub-cloning PBF’s WT 3’UTR microRNA 
target  site  into  a  GFP  vector  it  could  be  observed  whether  hsa-miR-122-5p  caused  an 
inhibition of GFP expression. 
 
If the observation of hsa-miR-122-5p decreasing PBF protein levels was confirmed this would 
be very interesting, as it complements the observations made by Li, C., et al. who described 
miR-122 targeted PBF in a Huh7 hepatocellular carcinoma cell line (2012). Furthermore, as 
Li, C., et al. also observed low miR-122 levels correlated with an upregulation of PBF in 
HCC (Li, C., et al., 2012) this highlights the importance of investigating hsa-miR-122 and 
PBF in the context of thyroid cancer. In a future investigation it would be interesting to 
investigate whether the targeting of PBF by hsa-miR-122-5p in SW1736 cells, an anaplastic 
thyroid carcinoma cell line, can be translated into cases of ATC in patients. This could be 
achieved  by  isolating  RNA  from  ATC  patient  samples  and  completing  qRT-PCR  using 
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TaqMan assays for PBF and hsa-miR-122-5p, with a negative correlation expected between 
these in thyroid tumour samples compared to in normal thyroid samples. In addition, it would 
be interesting to observe there correlation between PBF and hsa-miR-122-5p in MTC, FTC 
and PTC. 
 
4.2.  hsa-miR-124-3p  and  hsa-miR-506-3p  Decreased  PBF  mRNA  Expression  and 
 
Protein Levels 
 
 
The largest average decrease in PBF mRNA expression following transfection with a 
microRNA mimic was observed following hsa-miR-506-3p transfection in SW1736 cells. 
hsa-miR-506-3p transfection caused a decrease in PBF mRNA expression relative to the 
negative control of 35.54% in SW1736 cells (Figure 10), although it is important to note this 
was non-significant. In addition, the PBF protein levels at 25kDa in SW1736 cells were also 
decreased, by 33.66±38.85% (non-significant) (Figure 17B) strengthening the likelihood of 
hsa-miR-506-3p targeting PBF directly. 
 
As hsa-miR-506-3p shared a sequence similarity with hsa-miR-124-3p, resulting in binding at 
the same site on the 3’ UTR of PBF (Dweep, H., et al., 2011), it was interesting to observe 
that despite hsa-miR-124-5p not having as great an effect as hsa-miR-506-3p on PBF, it still 
caused an average decrease in PBF mRNA expression levels of 20.25% in SW1736 cells 
(non-significant) (Figure 10 and an average decrease in PBF protein levels of 26.21±25.48% 
(non-significant) at 25kDa in SW1736 cells (Figure 17B). However, due to there not being 
enough data within this investigation to observe whether a similar effect takes place in MCF7 
cells with hsa-miR-124-3p and hsa-miR-506-3p, as well as data not being significant for 
SW1736 cells, it would be essential to repeat these studies in both cell lines to identify 
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whether these microRNAs can negatively regulate PBF at both the mRNA expression and 
protein level. 
 
If hsa-miR-124-3p and hsa-miR-506-3p were confirmed to cause a decrease in PBF mRNA 
expression  and  protein  levels  this  would  be  an  interesting  observation  as  despite  the 
prediction of these microRNAs binding to the 3’ UTR of PBF (Dweep, H., et al., 2011) there 
is currently no previous evidence of these microRNAs altering PBF mRNA expression or 
protein levels. In addition, as both hsa-miR-124-3p and hsa-miR-506-3p are conserved 
microRNAs with a conserved binding site on PBF (Friedman, R.C., et al., 2009) (Figure 5A) 
this is suggestive of a potential important role in regulating the genome and as a result 
deregulation of these microRNAs may result in PBF overexpression, which may lead to the 
initiation of thyroid tumourigenesis. Previously, miR-124 has been shown to have a role as a 
tumour suppressor in bladder cancer by modulating the proliferation and aggressiveness of 
tumours (Xu X., et al., 2013) and hsa-miR-506 has been defined as a ‘master suppressor of 
EMT in breast cancer’ (Arora, H., et al., 2013), which is interesting due to the previous 
observations of PBF playing roles in both proliferation and invasion (Read, M.L., et al., 2011, 
Watkins, R.J., et al., 2010). 
 
4.3. Limitations 
 
 
The first limitation in this investigation was with respect to the initial stage in identifying 
microRNAs that target PBF. Due to both cost and time restrictions only five microRNAs were 
selected, which was only a handful of the potential microRNAs predicted to target PBF. 
Furthermore, due to the prediction software used being known to identify false positives, for 
example TargetScan has been described to identify false positives at a rate of 22-31% 
(Bentwich, I., 2005), there was potential for selected microRNAs to not actually target PBF. 
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Therefore, in the future it would be more useful to transfect a range of thyroid carcinoma cell 
lines with a large library of microRNA mimics, validate results by microarray and then select 
a larger group of microRNAs for qRT-PCR and Western blot analysis, as done in this 
investigation, to confirm whether they alter PBF mRNA expression and protein levels. 
 
Another limitation within this investigation, as a result of time restrictions, was the conditions 
used within this investigation, which were based upon previous observations in the McCabe 
lab and were not optimised. Therefore, if this investigation was repeated, it would be essential 
to optimise the time points for RNA isolation and more importantly protein harvest, as the 
exact half-life of PBF remains unknown. In addition, as the endogenous concentration of 
microRNAs was not quantified in either the SW1736 or MCF7 cells this may have resulted in 
a skew in results due to total microRNA concentration following transfection being different 
not only between microRNAs but also cell lines. Therefore, in a future investigation, qRT- 
PCR could be used to determine endogenous expression of selected microRNAs and then the 
concentrations of microRNA mimics required for transfection could be optimised and then 
normalised with respect to this, allowing a fair comparison to be made between individual 
microRNAs in each cell line. 
 
Potentially as a result of conditions not being optimised, there were some surprising 
inconsistencies observed between PBF mRNA expression and protein levels. For example, 
following the use of anti-PBF siRNA, which is designed to target PBF, there was an average 
decrease in PBF mRNA expression of 68.16% (p>0.05) in SW1736 cells (Figure 10) within 
the range expected from a siRNA. However, no significant decrease in PBF protein levels at 
either 25kDa or 30kDa were observed in SW1736 cells (Figure 19). This was unexpected as 
lowered mRNA levels account for >84% of the decreased protein production (Guo, H. et al., 
2010), which is not in line with what was observed in this investigation. Beyond optimising 
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conditions, another factor to consider is the PBF antibody used; as it is potentially unreliable, 
indicating Western blotting may not have been a good representation of the effect of 
microRNAs on PBF protein levels. In a future investigation it may be beneficial to either use 
a commercial antibody for Western blotting, for example PBF Antibody (E-8): sc-376960 
(Santa Cruz Biotechnology), which binds to the PBF C-terminus identifying PBF at between 
23kDa and 34kDa. Alternatively, another option in the future, which may solve the 
inconsistencies between mRNA and protein as well as issues with the antibody, would be via 
use of the novel QuantiGene FlowRNA in situ hybridisation assay (Affymetrix). Despite 
currently having no probe sets available for PBF, this assay has the benefit of being able to 
compare the kinetics of RNA expression and protein levels within a single cell and has been 
described to be useful for measuring target expression levels when antibodies are inadequate. 
 
4.4. Future Research 
 
 
Once conditions were optimised and if hsa-miR-122-5p, hsa-miR-124-3p and hsa-miR-506- 
 
3p were each confirmed to target PBF, it would then be useful to complete functional assays 
to determine the impact at the cellular level following microRNA mimic transfections of these 
microRNAs in a range of thyroid carcinoma cell lines. It would be interesting to investigate 
proliferation and invasion, using a MTT proliferation assay and invasion assay respectively, 
as not only are these factors characteristic of cancer, but PBF has also been shown to induce 
both proliferation (Read, M.L., et al., 2011) and invasion (Watkins, R.J., et al., 2010). 
However, as mentioned previously, due to the range of mRNA targets that each microRNA 
has it would be important to bear in mind that any functional effects observed may not 
necessarily be due to the effect of microRNAs on PBF. 
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Following this, it would then be essential to observe whether there is a correlation between 
hsa-miR-122-5p, hsa-miR-124-3p or hsa-miR-506-3p and PBF in thyroid cancer patient 
samples using qRT-PCR, in a method similar to that described in 4.1. If microRNAs were 
identified to be downregulated in thyroid tumours resulting in a subsequent increase in PBF, it 
would be interesting to determine how the microRNAs are downregulated.  One suggestion 
could be based on epigenetics, whereby DNA methylation causes a silencing of the genes that 
microRNAs  are  transcribed  from.  This  phenomenon  has  been  observed  previously  with 
respect to miR-124 gene promoters in an aggressive breast cancer cell line, where 
hypermethylation resulted in the decreased expression of miR-124 (Lv, X.B., et al., 2011). 
However, this was shown to be partially reversed by a DNA demethylating agent (Lv, X.B., et 
al., 2011) highlighting potential clinical relevance in restoring microRNA deregulation. 
 
Alternatively, due to previous studies suggesting that a re-introduction of specific microRNAs 
underexpressed in cancer cells may benefit in reversing tumourigenesis (Trang, P., et al., 
2009), another avenue of potential clinical relevance that could be investigated is the re- 
introduction of hsa-miR-122-5p, hsa-miR-124-3p or hsa-miR-506-3p into a system. It could 
then be observed whether PBF overexpression is decreased and consequently, whether there is 
a benefit in thyroid cancer prognosis. To assess this, an already established murine model 
could be used, whereby nude mice are injected with NIH-3T3 cells stably expressing PBF, 
which causes the subsequent growth of aggressive tumours (Stratford, A.L., et al., 2005). 
Following  this,  administration  of  hsa-miR-122-5p,  hsa-miR-124-3p  or  hsa-miR-506-3p 
mimics respectively to the nude mice would allow determination of whether there is an 
improvement within these mice compared to those treated with a negative control. In addition, 
further investigations could be completed by isolating RNA from normal and cancerous tissue 
and  completing  qRT-PCR  to  determine  whether  there  is  also  a  reduction  in  PBF  upon 
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microRNA administration. If these in vivo studies did show a decrease in PBF and a 
subsequent phenotypic benefit, the application to humans could be extended. 
 
4.5. Conclusion 
 
 
Results indicated hsa-miR-122-5p decreased PBF protein significantly at 25kDa in SW1736 
cells although; this decrease was not reflected in PBF mRNA expression. Furthermore, hsa- 
miR-124-3p and hsa-miR-506-3p decreased PBF mRNA expression as well as PBF protein 
levels at 25kDa in SW1736 cells, albeit non-significantly. Due to limitations within this 
investigation, these preliminary findings of hsa-miR-122-5p, hsa-miR-124-3p and hsa-miR- 
506-3p targeting PBF would need to be confirmed by optimising conditions and repeating 
these experiments. 
 
If these microRNAs were confirmed to target PBF, it would suggest a mechanism of PBF 
regulation  whereby  upon  specific  microRNA  deregulation  an  overexpression  of  PBF  is 
caused, resulting in thyroid tumourigenesis. Due to the emerging importance of microRNAs 
as biomarkers and therapeutics the identification of specific microRNAs that play a role in 
thyroid tumourigenesis may be clinically relevant. 
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6. APPENDIX 
 
 
 
B 
 
A  
Supplementary figure 1: 18s example plot from 7500 system software 
A)  Raw  data  from  7500  system  software  indicating  cDNA  and  RT  negative  mastermix 
controls were at higher average CT values compared to data from samples containing cDNA 
and RT positive mastermix. 
B) Plots for 18s for samples containing cDNA and RT positive mastermix can be seen close 
together with cDNA and RT negative mastermix control plots at a higher cycle number. The 
threshold bar can be seen at 1.000e-003 Delta Rn. 
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B 
A   
Supplementary figure 2: PBF example plot from 7500 system software 
A)  Raw  data  from  7500  system  software  indicating  cDNA  and  RT  negative  mastermix 
controls were at higher average CT values compared to data from samples containing cDNA 
and RT positive mastermix. 
B) Plots for PBF for samples containing cDNA and RT positive mastermix can be seen close 
together with cDNA and RT negative mastermix control plots at a higher cycle number. The 
threshold bar can be seen at 1.000e-003 Delta Rn. 
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